# LUME-Meso (NCT01907100)

> Nintedanib (BIBF 1120) in Mesothelioma

No report yet. It can be ordered.

- Drugs tested: nintedanib
- Indication: unresectable malignant pleural mesothelioma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01907100
- Phase: PHASE2, PHASE3
- Status: TERMINATED
- Sponsor: Boehringer Ingelheim
- Conditions: Mesothelioma
- Interventions: Nintedanib; Pemetrexed; Cisplatin; Cisplatin; Pemetrexed; Placebo
- Enrollment: 545
- Primary outcome: Progression-Free Survival (PFS)

## Indexed commentary on LUME-Meso so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=lume-meso-nct01907100